Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
ADC Therapeutics
ADCT
ADC Therapeutics
Regulatory And Pipeline Risks Will Stunt Progress But Hope Remains
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
12 Aug 25
Updated
12 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$5.00
37.4% undervalued
intrinsic discount
12 Aug
US$3.13
Loading
1Y
12.2%
7D
16.8%
Author's Valuation
US$5.0
37.4% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$5.0
37.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-237m
184m
2017
2019
2021
2023
2025
2027
2028
Revenue US$131.1m
Earnings US$18.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
37.42%
Biotech revenue growth rate
13.35%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.29%
Calculation
US$18.58m
Earnings '28
x
36.98x
PE Ratio '28
=
US$687.11m
Market Cap '28
US$687.11m
Market Cap '28
/
107.18m
No. shares '28
=
US$6.41
Share Price '28
US$6.41
Share Price '28
Discounted to 2025 @ 8.64% p.a.
=
US$5.00
Fair Value '25
